Real-world outcomes with novel therapies in R/R DLBCL.
Jennifer L. Crombie(Dana-Farber Cancer Institute), Anupama Kalsekar(Genmab (United States)), Jon Ukropec(Genmab (United States)), Rajesh Kamalakar(AbbVie (United States)), Monika Jun(Genmab (United States)), Tongsheng Wang(Genmab (United States)), Julie Blædel(Genmab (United States)), Alex Mutebi(Genmab (United States)), Anindit Chibber(Genmab (United States)), Anthony Wang(University of California, Los Angeles)
Cited by 3
Related Papers
Detection of human brain tumor infiltration with quantitative stimulated Raman scattering microscopy
|Science Translational Medicine|2015|323
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
|Blood|2019|187
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
|Blood|2024|132
The treatment of Burkitt lymphoma in adults
|Blood|2020|105